You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Bio-tissue Oxygenation Nanophosphor Enabled Sensing (BONES) system for Quantifying Hypoxia in Bone Marrow

    SBC: SIGRAY, INC.            Topic: 400

    Project Summary/Abstract Low oxygen (hypoxic) environments are known to be important for maintaining the small number of adult stem cells in the human body, such as in bone marrow. These conditions are also believed to enable dormant cancer cells to survive and metastasize years or decades after the original tumor has been destroyed and the reason why bone marrow is one of the most common sites of ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. MiGo: wearable sensors that combine actionable data with a behavioral intervention to improve function after stroke

    SBC: FLINT REHABILITATION DEVICES, LLC            Topic: NICHD

    One of the most impenetrable problems challenging full recovery after stroke is the gap between motor capacity that a stroke survivor regains (i.e. what they can do) and how they engage in home and community activities (i.e. what they choose to do). To address this challenge, Flint Rehab developed MiGo, a novel multi-sensor activity tracker specifically designed for stroke survivors. The unique fe ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Development of low-cost, field-ready nanobodies against snake venom

    SBC: Venomyx, Inc.            Topic: 400

    PROJECT SUMMARY Snakebite constitutes one of the largest and most tenacious public health issues on a global scale. Every year, up to 5 million people will suffer snakebite envenomation, causing approximately 125,000 deaths and 400,000 left with permanent physical disability. Nearly 8,000 snakebites occur in the United States each year. The regions most affected are in Asia, Africa, Latin America, ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Engineered Cyclodextrins to Address 7-ketocholesterol-Associated Diseases ofAging

    SBC: UNDERDOG PHARMACEUTICALS, INC.            Topic: NIA

    Project Summary/Abstract Underdog Pharmaceuticals, Inc. (UDP), in collaboration with the SENS Research Foundation (SRF), aims to demonstrate that 7-ketocholesterol (7KC) is elevated in red blood cells (RBCs) in Atherosclerosis and Alzheimer’s disease. 7KC is primarily created by non-enzymatic oxidation of cholesterol. With only a few exceptions, human tissues lack the ability to metabolize or ex ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Eliminating Acne Through Photo-Inactivation Catalase

    SBC: PULSETHERA CORP            Topic: NIAMS

    PROJECT SUMMARYAcne vulgaris is a skin inflammatory condition affecting 80% of young adults and can frequently induce permanent disfigurement even with appropriate treatment. Acne is caused by C. acnes in the setting of hormonal changes and sebum induction that accompany adolescence. The mainstay of therapeutics consist of eradicating C. acnes and reducing inflammation. However, treatment is prolo ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Safe in Utero Gene Editing Technology in Mice

    SBC: Acrigen Biosciences, Inc.            Topic: 100

    Abstract In the nearly 20 years since the groundbreaking sequencing of the human genome, the potential for precision genetic medicine has still not been realized. Advances in sequencing have vastly increased our ability to screen patients (including parents and fetuses) for genetic abnormalities, dramatically expanding identification of hereditary diseases in the prenatal period. This opens the do ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. A therapeutic for Lyme disease based on Peptidoglycan Recognition Protein 1

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    ABSTRACTLyme disease, the most common vector-borne illness in North America, is caused by the spirochete B. burgdorferi. Infection begins in the skin following an infected tick-bite and acute illness is characterized by headache, fever and myalgia. Currently, there is no human vaccine against Lyme disease and therapeutic administration of antibiotics remains the recommended treatment option. In th ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma

    SBC: ROCK IMMUNE LLC            Topic: 102

    Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skin lesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are the two most common types of CTCL. Although treatments exist, they are mainly palliative with low response and durability of response without any cure. The objective response rate ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting Covid-19 with a Therapeutic Interfering Particle

    SBC: ALEPH THERAPEUTICS INC            Topic: NIAID

    SUMMARYThe Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currently the most important public health crisis in the world. Given the unprecedented scope of this disease, it is critical to explore novel strategies to mitigate this crisis. Aleph Therapeutics and UCSF have jointly developed eTIP1, a Therapeutic Interfering Particle. eTIP1 was developed under a DARPA ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Using Rendever to improve the quality of life of older adults with cognitive impairments in senior living communities and their family members who live at a distance.

    SBC: RENDEVER, INC.            Topic: NIA

    ABSTRACTThe United States is experiencing a public health crisis on a massive scale due to the number of people with dementia, lack of cures, and challenges associated with caregiving for this population.1,2 until cures for the dementias are discovered, new technologies and interventions are imperative that can reduce the stress and emotional burden of Alzheimer’s disease (AD) and Alzheimer’s ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government